Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
ICU
Hospitalization
Serious outcomes
Recovery
Cases
Viral clearance
RCTs
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 antiandrogen studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 59% 6 523 Improvement, Studies, Patients Relative Risk, 95% CI With exclusions 48% 4 166 Mortality 95% 1 118 ICU admission 34% 2 166 Hospitalization 25% 1 118 Recovery 68% 2 357 Cases 75% 1 0 Viral clearance 38% 1 270 RCTs 62% 1 87 Peer-reviewed 67% 4 253 Prophylaxis 15% 3 118 Early 68% 2 357 Late 81% 1 48 Antiandrogens for COVID-19 c19early.com/aa Dec 5, 2021 Favors antiandrogen Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 77% 0.23 [0.08-0.66] recov. time 8 (n) 262 (n) Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 62% 0.38 [0.18-0.82] no recov. 7/44 18/43 Tau​2 = 0.00; I​2 = 0.0% Early treatment 68% 0.32 [0.17-0.59] 7/52 18/305 68% improvement Goren 81% 0.19 [0.03-1.28] ICU 1/12 17/36 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 81% 0.19 [0.03-1.28] 1/12 17/36 81% improvement Montopoli 75% 0.25 [0.09-0.76] severe case Improvement, RR [CI] Treatment Control Bennani 95% 0.05 [0.00-2062] death 0/4 18/114 Lazzeri -23% 1.23 [0.81-1.87] death/ICU Tau​2 = 0.33; I​2 = 24.1% Prophylaxis 15% 0.85 [0.30-2.45] 0/4 18/114 15% improvement All studies 59% 0.41 [0.17-0.99] 8/68 53/455 59% improvement 6 antiandrogen COVID-19 studies c19early.com/aa Dec 5, 2021 Tau​2 = 0.64; I​2 = 70.2%; Z = 1.98 Effect extraction pre-specified Favors antiandrogen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Goren 81% 0.19 [0.03-1.28] ICU 1/12 17/36 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 81% 0.19 [0.03-1.28] 1/12 17/36 81% improvement Montopoli 75% 0.25 [0.09-0.76] severe case Improvement, RR [CI] Treatment Control Bennani 95% 0.05 [0.00-2062] death 0/4 18/114 Lazzeri -23% 1.23 [0.81-1.87] death/ICU Tau​2 = 0.33; I​2 = 24.1% Prophylaxis 15% 0.85 [0.30-2.45] 0/4 18/114 15% improvement All studies 48% 0.52 [0.15-1.83] 1/16 35/150 48% improvement 4 antiandrogen COVID-19 studies after exclusions c19early.com/aa Dec 5, 2021 Tau​2 = 0.75; I​2 = 49.2%; Z = 1.01 Effect extraction pre-specified Favors antiandrogen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bennani 95% 0.05 [0.00-2062] 0/4 18/114 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 95% 0.05 [0.00-2062] 0/4 18/114 95% improvement All studies 95% 0.05 [0.00-2062] 0/4 18/114 95% improvement 1 antiandrogen COVID-19 mortality result c19early.com/aa Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.55 Favors antiandrogen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Goren 81% 0.19 [0.03-1.28] 1/12 17/36 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 81% 0.19 [0.03-1.28] 1/12 17/36 81% improvement Bennani -119% 2.19 [0.37-12.9] 1/4 13/114 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis -119% 2.19 [0.37-12.9] 1/4 13/114 -119% improvement All studies 34% 0.66 [0.06-7.28] 2/16 30/150 34% improvement 2 antiandrogen COVID-19 ICU results c19early.com/aa Dec 5, 2021 Tau​2 = 2.11; I​2 = 70.5%; Z = 0.34 Favors antiandrogen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bennani 25% 0.75 [0.28-2.02] hosp. 2/4 76/114 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 25% 0.75 [0.28-2.02] 2/4 76/114 25% improvement All studies 25% 0.75 [0.28-2.02] 2/4 76/114 25% improvement 1 antiandrogen COVID-19 hospitalization result c19early.com/aa Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 0.57 Favors antiandrogen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Goren 81% 0.19 [0.03-1.28] ICU 1/12 17/36 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 81% 0.19 [0.03-1.28] 1/12 17/36 81% improvement Montopoli 75% 0.25 [0.09-0.76] severe case Improvement, RR [CI] Treatment Control Bennani 95% 0.05 [0.00-2062] death 0/4 18/114 Lazzeri -23% 1.23 [0.81-1.87] death/ICU Tau​2 = 0.33; I​2 = 24.1% Prophylaxis 15% 0.85 [0.30-2.45] 0/4 18/114 15% improvement All studies 48% 0.52 [0.15-1.83] 1/16 35/150 48% improvement 4 antiandrogen COVID-19 serious outcomes c19early.com/aa Dec 5, 2021 Tau​2 = 0.75; I​2 = 49.2%; Z = 1.01 Effect extraction pre-specified Favors antiandrogen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 77% 0.23 [0.08-0.66] recov. time 8 (n) 262 (n) Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 62% 0.38 [0.18-0.82] no recov. 7/44 18/43 Tau​2 = 0.00; I​2 = 0.0% Early treatment 68% 0.32 [0.17-0.59] 7/52 18/305 68% improvement All studies 68% 0.32 [0.17-0.59] 7/52 18/305 68% improvement 2 antiandrogen COVID-19 recovery results c19early.com/aa Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 3.62 Favors antiandrogen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Montopoli 75% 0.25 [0.09-0.65] Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 75% 0.25 [0.09-0.65] 75% improvement All studies 75% 0.25 [0.09-0.67] 75% improvement 1 antiandrogen COVID-19 case result c19early.com/aa Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.75 Favors antiandrogen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 38% 0.62 [0.42-0.91] viral time 8 (n) 262 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 38% 0.62 [0.42-0.91] 0/8 0/262 38% improvement All studies 38% 0.62 [0.42-0.91] 0/8 0/262 38% improvement 1 antiandrogen COVID-19 viral clearance result c19early.com/aa Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.43 Favors antiandrogen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani (DB RCT) 62% 0.38 [0.18-0.82] no recov. 7/44 18/43 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 62% 0.38 [0.18-0.82] 7/44 18/43 62% improvement All studies 62% 0.38 [0.18-0.82] 7/44 18/43 62% improvement 1 antiandrogen COVID-19 Randomized Controlled Trials c19early.com/aa Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 2.48 Effect extraction pre-specified Favors antiandrogen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani (DB RCT) 62% 0.38 [0.18-0.82] no recov. 7/44 18/43 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 62% 0.38 [0.18-0.82] 7/44 18/43 62% improvement Goren 81% 0.19 [0.03-1.28] ICU 1/12 17/36 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment 81% 0.19 [0.03-1.28] 1/12 17/36 81% improvement Montopoli 75% 0.25 [0.09-0.76] severe case Improvement, RR [CI] Treatment Control Bennani 95% 0.05 [0.00-2062] death 0/4 18/114 Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 76% 0.24 [0.03-1.71] 0/4 18/114 76% improvement All studies 67% 0.33 [0.17-0.65] 8/60 53/193 67% improvement 4 antiandrogen COVID-19 peer reviewed trials c19early.com/aa Dec 5, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 3.24 Effect extraction pre-specified Favors antiandrogen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 77% 0.23 [0.08-0.66] recov. time 8 (n) 262 (n) Improvement, RR [CI] Treatment Control Cadegiani 83% 0.17 [0.06-0.51] recov. time 8 (n) 262 (n) Cadegiani 38% 0.62 [0.42-0.91] viral time 8 (n) 262 (n) Cadegiani (DB RCT) 62% 0.38 [0.18-0.82] no recov. 7/44 18/43 Cadegiani (DB RCT) 44% 0.56 [0.40-0.79] recov. time 44 (n) 43 (n) Cadegiani (DB RCT) 40% 0.60 [0.44-0.81] recov. time 44 (n) 43 (n) Goren 81% 0.19 [0.03-1.28] ICU 1/12 17/36 Goren 86% 0.14 [0.02-0.94] ICU 1/12 38/65 Goren -50% 1.50 [0.15-15.1] death 1/12 2/36 Goren -35% 1.35 [0.17-11.1] death 1/12 4/65 Montopoli 75% 0.25 [0.09-0.76] severe case Montopoli 75% 0.25 [0.09-0.65] cases Bennani 95% 0.05 [0.00-2062] death 0/4 18/114 Bennani -119% 2.19 [0.37-12.9] ICU 1/4 13/114 Bennani 25% 0.75 [0.28-2.02] hosp. 2/4 76/114 Bennani 8% 0.92 [0.16-5.15] severe case 1/4 31/114 Lazzeri -23% 1.23 [0.81-1.87] death/ICU antiandrogen COVID-19 outcomes c19early.com/aa Dec 5, 2021 Favors antiandrogen Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit